期刊文献+

脂微球前列腺素E1对糖尿病血小板活化及尿微量蛋白的影响 被引量:3

原文传递
导出
摘要 目的探讨脂微球前列腺素E1对糖尿病血小板活化及尿微量蛋白的的影响。方法选取76例2型糖尿病患者观察治疗前后血小板活化指标CD62p、CD63、凝血酶敏感蛋白(TSD)及尿微量蛋白的变化。结果治疗前后血小板活化指标CD62p[(22.4±4.7)%与(14.3±6.7)%)]、CD63[(17.7±3.1)%与(10.1±4.3)%]、TSD[(12.3±4.6)%与(10.9±2.1)%]及尿微量蛋白:尿微量白蛋白[(37.64±7.31)g/L与(19.40±5.73)g/L]、α1微球蛋白[(14.67±5.33)g/L与(10.57±4.67)g/L]、转铁蛋白[(2.14±0.31)g/L与(1.05±0.20)g/L]、尿IgG[(6.87±2.14)g/L与(3.57±0.98)g/L]比较,差异均有统计学意义(P均〈0.01)。结论脂微球前列腺素E1能减少糖尿病患者的血小板活化,保护血管内皮功能,保护肾功能。
出处 《中国综合临床》 2009年第12期1269-1270,共2页 Clinical Medicine of China
  • 相关文献

参考文献5

二级参考文献20

  • 1吴逸南,葛志明,李永红,李方,张成秋,张运.氯沙坦对血管内皮损伤后血小板活化及AngⅡAT_1受体表达的影响[J].山东大学学报(医学版),2006,44(4):341-344. 被引量:2
  • 2廖二元 超楚生.内分泌学[M].北京:人民卫生出版社,2001.610-611.
  • 3Bakker AJ.Detection of microalbminuria:Receiver operating characteristic curve analysis favors albumin-to-creatinine ratio over albumin concentration[J].Diabetes Care,1999,22 (2):307 -312.
  • 4Mettinen H,Haffner SM,Lehto S,et al.Proteinuria perdicts stroke and other atherosclerotic vascular disease events in nondiabetic and non-insulin-dependent diabetic subjects[J].Stroke,1996,27 (11):2033 -2036.
  • 5Dinneen SF,Gerstein HC.The association of microalbunminuria and mortality in non-insulin-dependent diabetes mellites[J].Arch Int Med,1997,157(10):1413-1418.
  • 6Diercks GF,Van Boven AJ,Hillege JL,etal.The importance of microabia as a cardiovascular risk indicator[J].Can J Cario1,2002,18(5):525-528.
  • 7Deckert T.Nephropathy and coronary death:the fatal twins in diabetes mellitus[J].Nephro Dial Transplant,1994,9 (8):1069-1073.
  • 8Cart ME. Diabetes mellitus:a hypercoagulable state[J]. J Diab complic, 2001 ; 15( 1 ) :44-54.
  • 9Ceriello A. coagulalion activation in diabetes mellitus the role of hyperglycaemia and therapeutic prospects[J]. Diabetologia, 1993 ;36 (11):1 119-1 125.
  • 10Pei W,Baron H,MμLler-Myhsok B,etal.Suport for linkage of familial combined hyperlipidemia to chromosome1q21-q23 in Chinese and German families[J].Clin Genet,2000,57(1):29-34.

共引文献21

同被引文献21

  • 1周巧玲,成小苗,欧阳春,解勤之,陈立平,胡杨清.前列腺素E1对原发性肾病综合征作用初探(英文)[J].中国医学工程,2002,10(6):37-39. 被引量:8
  • 2MARSHALL S M.Recent advances in diabetic nephropathy[J].Clin Med,2004,4(3):277-283.
  • 3COLLIER A,RUMLEY A,RUMILEY A G,et al.Free radical activity and hemostatic factors in NIDDM patients with and without microalbuminuria[J].Diabetes,1992,41:909-912.
  • 4EL-KHAWANDC,JAMARTJ,DONCKIERJ,etal.Hemostasis variables in type Ⅰ diabetic patients without demonstrable vascular complications[J].Diabetes Care,1993,16:1137-1145.
  • 5CYMERYS M,PUPEK-MUSIALIK D.The role of rheological factors in the pathogenesis of diabetic nephropathy[J].Poi Merkur Lekarski,2000,8(49):489-493.
  • 6NEGREAN V,SUEIU I,SAMPELEAN D,et al.Rheological changes in diabetic microangiopathy[J].Rom J Intern Med,2004,42(2):407-413.
  • 7Carlsson M, Wessman Y, Almgren P, et al. High levels of nonesterified fatty acids are associated with increased familial risk of cardiovascular disease [ J ] . Arterioscler Thromb Vasc Biol, 2000,20(6) :1588-1594.
  • 8Huang Y,Marui A,Sakaguchi H,et al.Sustained release of prostaglandin E1potentiates the impaired therapeutic angiogenesis by basic fibroblast growth factor in diabetic murine hindimb is-chemia[J].Cire J,2008,72(10):1693-1699.
  • 9Tuttle KR.Linking metalism and immunology:diabetic nephropathy is anin flammatorydisease[J].J Am Soe Nephrol,2005,16(6):1537-1538.
  • 10张旭 吕豪 孙振学.银杏达莫联合前列腺素E1治疗糖尿病并发外周动脉疾病的临床研究.中国基层医药,2010,17(2):81-82.

引证文献3

二级引证文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部